chlorpromazine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
621 50-53-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • chlorpromazine
  • 2-Chloropromazine
  • chlordelazin
  • chlorderazin
  • thorazine
  • contomin
  • chlorpromazine hydrochloride
  • chlorpromazine HCl
The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.
  • Molecular weight: 318.86
  • Formula: C17H19ClN2S
  • CLOGP: 5.50
  • LIPINSKI: 1
  • HAC: 2
  • HDO: 0
  • TPSA: 6.48
  • ALOGS: -4.88
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.30 g O
0.10 g P
0.30 g R

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 400 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 52.37 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 25 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 10 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 16 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.06 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 11 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Sept. 18, 1957 FDA GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neuroleptic malignant syndrome 223.99 21.43 78 7504 11052 50586490
Sopor 173.52 21.43 76 7506 19803 50577739
Drug abuse 170.39 21.43 108 7474 59738 50537804
Toxicity to various agents 152.99 21.43 173 7409 212326 50385216
Electrocardiogram QT prolonged 138.64 21.43 90 7492 51796 50545746
Catatonia 131.43 21.43 40 7542 3696 50593846
Overdose 109.37 21.43 102 7480 99625 50497917
Suicide attempt 103.28 21.43 75 7507 51657 50545885
Aggression 91.32 21.43 50 7532 21066 50576476
Intentional self-injury 89.79 21.43 51 7531 23061 50574481
Coma 81.98 21.43 68 7514 56811 50540731
Agitation 81.51 21.43 66 7516 53318 50544224
Mania 73.93 21.43 35 7547 10881 50586661
Psychotic disorder 68.61 21.43 42 7540 21770 50575772
Mental disorder 58.29 21.43 38 7544 21953 50575589
Intentional overdose 55.46 21.43 57 7525 62447 50535095
Tardive dyskinesia 51.32 21.43 24 7558 7255 50590287
Delusion 51.20 21.43 27 7555 10542 50587000
Hallucination, auditory 50.82 21.43 27 7555 10701 50586841
Depressed level of consciousness 49.04 21.43 49 7533 51904 50545638
Psychomotor hyperactivity 48.61 21.43 25 7557 9276 50588266
Cardiac arrest 48.22 21.43 61 7521 83590 50513952
Drug interaction 47.33 21.43 97 7485 199524 50398018
Completed suicide 46.35 21.43 76 7506 131813 50465729
Pneumonia aspiration 44.49 21.43 37 7545 30967 50566575
Sedation 42.83 21.43 36 7546 30574 50566968
Stereotypy 41.70 21.43 10 7572 372 50597170
Torsade de pointes 40.33 21.43 24 7558 11811 50585731
Somnolence 39.93 21.43 78 7504 154907 50442635
Hepatocellular injury 39.39 21.43 32 7550 25915 50571627
Grandiosity 39.14 21.43 9 7573 278 50597264
Arthralgia 39.05 21.43 9 7573 438693 50158849
Miosis 38.98 21.43 19 7563 6291 50591251
Salivary hypersecretion 38.19 21.43 19 7563 6572 50590970
Behaviour disorder 37.75 21.43 14 7568 2366 50595176
Poisoning deliberate 37.72 21.43 20 7562 7892 50589650
Tachycardia 37.08 21.43 59 7523 99704 50497838
Eosinophilic myocarditis 36.99 21.43 9 7573 356 50597186
Disorganised speech 36.51 21.43 11 7571 980 50596562
Hypotonia neonatal 36.45 21.43 11 7571 986 50596556
Pain 34.83 21.43 22 7560 578881 50018661
Epileptic encephalopathy 34.17 21.43 8 7574 268 50597274
Premature delivery 33.45 21.43 28 7554 23635 50573907
Mutism 32.92 21.43 11 7571 1370 50596172
Lactate pyruvate ratio increased 30.22 21.43 6 7576 90 50597452
Pain in extremity 30.14 21.43 3 7579 272862 50324680
Gaze palsy 29.34 21.43 10 7572 1323 50596219
Fatigue 29.34 21.43 38 7544 707563 49889979
Psychomotor skills impaired 28.60 21.43 11 7571 2053 50595489
Muscle rigidity 28.55 21.43 18 7564 9811 50587731
Illusion 28.39 21.43 9 7573 950 50596592
Confusional state 28.29 21.43 76 7506 185852 50411690
Extrapyramidal disorder 27.95 21.43 19 7563 11751 50585791
Drug use disorder 27.60 21.43 12 7570 3060 50594482
Newborn persistent pulmonary hypertension 27.55 21.43 6 7576 144 50597398
Abnormal behaviour 27.24 21.43 23 7559 19635 50577907
Altered state of consciousness 27.06 21.43 24 7558 21886 50575656
Myocarditis 26.77 21.43 16 7566 7931 50589611
Blood citric acid increased 26.29 21.43 5 7577 59 50597483
Dysarthria 25.98 21.43 30 7552 37373 50560169
Cardio-respiratory arrest 24.46 21.43 35 7547 53857 50543685
Schizoaffective disorder 24.43 21.43 10 7572 2196 50595346
Dyspnoea 24.14 21.43 28 7554 547580 50049962
Tremor 23.90 21.43 53 7529 114850 50482692
Mitochondrial enzyme deficiency 22.44 21.43 4 7578 32 50597510
Bradyphrenia 22.34 21.43 13 7569 6139 50591403
Maternal exposure during pregnancy 22.00 21.43 63 7519 159715 50437827
Anger 21.60 21.43 16 7566 11317 50586225

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neuroleptic malignant syndrome 303.69 16.72 132 9190 16016 29549189
Catatonia 119.38 16.72 47 9275 4421 29560784
Decreased eye contact 102.61 16.72 25 9297 460 29564745
Oppositional defiant disorder 100.36 16.72 25 9297 506 29564699
Emotional poverty 98.33 16.72 24 9298 445 29564760
Psychotic disorder 94.45 16.72 66 9256 20288 29544917
Aggression 92.70 16.72 82 9240 35459 29529746
Extrapyramidal disorder 87.74 16.72 50 9272 10781 29554424
Bruxism 85.24 16.72 28 9294 1559 29563646
Psychomotor hyperactivity 83.33 16.72 44 9278 8169 29557036
Tardive dyskinesia 76.54 16.72 36 9286 5222 29559983
Homicidal ideation 76.12 16.72 29 9293 2495 29562710
Foetal disorder 68.17 16.72 20 9302 763 29564442
Sedation 66.08 16.72 50 9272 17355 29547850
Parkinsonism 65.47 16.72 36 9286 7242 29557963
Foetal exposure during pregnancy 63.26 16.72 65 9257 33802 29531403
Drug withdrawal syndrome neonatal 61.26 16.72 27 9295 3368 29561837
Neutropenia neonatal 58.16 16.72 17 9305 640 29564565
Suicide attempt 57.52 16.72 62 9260 34048 29531157
Dyskinesia 55.71 16.72 48 9274 20013 29545192
Schizophrenia 49.67 16.72 29 9293 6536 29558669
Hyperkinesia 46.88 16.72 18 9304 1581 29563624
Choreoathetosis 46.85 16.72 16 9306 1004 29564201
Crying 46.84 16.72 26 9296 5325 29559880
Delusion of grandeur 46.56 16.72 13 9309 414 29564791
Trismus 46.49 16.72 20 9302 2353 29562852
Dystonia 43.77 16.72 31 9291 9718 29555487
Sopor 40.58 16.72 31 9291 10903 29554302
Irritability 40.41 16.72 42 9280 22110 29543095
Suicidal ideation 40.08 16.72 52 9270 34664 29530541
Coordination abnormal 39.99 16.72 26 9296 7088 29558117
Hallucination, auditory 39.62 16.72 29 9293 9564 29555641
Congenital cerebrovascular anomaly 35.79 16.72 6 9316 12 29565193
Insomnia 35.40 16.72 83 9239 88678 29476527
Blood creatine phosphokinase increased 35.16 16.72 53 9269 40591 29524614
Dextrocardia 34.81 16.72 8 9314 113 29565092
Somnolence 34.40 16.72 85 9237 93870 29471335
Affect lability 33.86 16.72 18 9304 3384 29561821
Premature baby 33.76 16.72 34 9288 17246 29547959
Agitation 33.63 16.72 59 9263 51245 29513960
Foetal alcohol syndrome 33.37 16.72 8 9314 137 29565068
Intentional self-injury 32.94 16.72 29 9293 12432 29552773
Poor feeding infant 32.62 16.72 10 9312 444 29564761
Priapism 31.79 16.72 19 9303 4469 29560736
Speech disorder 31.57 16.72 38 9284 23478 29541727
Arthralgia 30.50 16.72 4 9318 139613 29425592
Sleep disorder 30.46 16.72 38 9284 24348 29540857
Salivary hypersecretion 29.70 16.72 22 9300 7387 29557818
Streptococcal infection 29.21 16.72 18 9304 4470 29560735
Mood altered 27.93 16.72 22 9300 8089 29557116
Depressed mood 27.88 16.72 30 9292 16418 29548787
Floppy iris syndrome 27.42 16.72 8 9314 299 29564906
Dyspnoea 27.33 16.72 38 9284 326694 29238511
Tachycardia 27.01 16.72 66 9256 72344 29492861
Neutrophil count increased 26.97 16.72 28 9294 14714 29550491
Affective disorder 26.84 16.72 15 9307 3111 29562094
Spasmodic dysphonia 26.50 16.72 6 9316 79 29565126
Electrocardiogram QT prolonged 25.57 16.72 43 9279 36094 29529111
Long QT syndrome 25.49 16.72 13 9309 2245 29562960
Low birth weight baby 25.10 16.72 19 9303 6589 29558616
Pneumonia aspiration 25.05 16.72 43 9279 36694 29528511
Pain in extremity 24.51 16.72 3 9319 110430 29454775
Cerebral amyloid angiopathy 24.29 16.72 6 9316 117 29565088
Overdose 23.88 16.72 67 9255 79752 29485453
Neuroblastoma 23.61 16.72 6 9316 132 29565073
Poor quality sleep 23.58 16.72 19 9303 7214 29557991
Pain 22.61 16.72 13 9309 171419 29393786
Acanthosis nigricans 22.58 16.72 6 9316 158 29565047
Drug interaction 22.57 16.72 122 9200 197263 29367942
Mental impairment 21.65 16.72 20 9302 9121 29556084
Treatment noncompliance 21.52 16.72 32 9290 24195 29541010
Portal tract inflammation 21.41 16.72 5 9317 76 29565129
Faecal vomiting 21.28 16.72 7 9315 391 29564814
Drug screen false positive 21.18 16.72 8 9314 672 29564533
Intentional overdose 21.08 16.72 41 9281 38487 29526718
Poisoning deliberate 20.72 16.72 16 9306 5715 29559490
Pulmonary valve incompetence 20.66 16.72 8 9314 719 29564486
Mania 20.60 16.72 19 9303 8644 29556561
Psychomotor retardation 19.53 16.72 12 9310 2964 29562241
Drug withdrawal syndrome 19.29 16.72 26 9296 17958 29547247
Neutropenia 18.99 16.72 87 9235 131624 29433581
Antipsychotic drug level increased 18.58 16.72 12 9310 3231 29561974
Hiccups 18.36 16.72 18 9304 8835 29556370
Toxicity to various agents 18.27 16.72 105 9217 173556 29391649
Pruritus 18.26 16.72 7 9315 116842 29448363
Delirium 18.09 16.72 39 9283 39358 29525847
Completed suicide 18.07 16.72 66 9256 90180 29475025
Sinus tachycardia 18.05 16.72 23 9299 15046 29550159
Diarrhoea 18.00 16.72 50 9272 332648 29232557
Intestinal obstruction 17.89 16.72 26 9296 19251 29545954
Echopraxia 17.58 16.72 3 9319 7 29565198
Torticollis 17.49 16.72 8 9314 1087 29564118
Depressed level of consciousness 17.46 16.72 37 9285 36905 29528300
Altered state of consciousness 17.27 16.72 26 9296 19863 29545342
Drug resistance 17.08 16.72 27 9295 21513 29543692
Therapy non-responder 17.03 16.72 33 9289 30878 29534327
Encephalopathy 16.93 16.72 33 9289 31010 29534195
Respiratory depression 16.77 16.72 21 9301 13502 29551703

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neuroleptic malignant syndrome 514.52 17.03 200 14815 24796 64458921
Catatonia 245.91 17.03 85 14930 7535 64476182
Sopor 190.74 17.03 106 14909 29555 64454162
Aggression 168.54 17.03 115 14900 46117 64437600
Psychomotor hyperactivity 139.94 17.03 68 14947 14383 64469334
Suicide attempt 136.76 17.03 121 14894 70886 64412831
Tardive dyskinesia 132.42 17.03 57 14958 9121 64474596
Drug abuse 131.62 17.03 158 14857 132216 64351501
Toxicity to various agents 129.03 17.03 270 14745 363243 64120474
Psychotic disorder 125.96 17.03 86 14929 34492 64449225
Extrapyramidal disorder 120.56 17.03 68 14947 19484 64464233
Overdose 114.25 17.03 162 14853 159404 64324313
Oppositional defiant disorder 110.08 17.03 25 14990 461 64483256
Electrocardiogram QT prolonged 106.70 17.03 111 14904 79337 64404380
Decreased eye contact 103.77 17.03 26 14989 739 64482978
Intentional self-injury 98.17 17.03 69 14946 28975 64454742
Sedation 94.79 17.03 78 14937 41384 64442333
Agitation 93.58 17.03 109 14906 88258 64395459
Emotional poverty 85.82 17.03 22 14993 687 64483030
Somnolence 78.81 17.03 157 14858 203488 64280229
Coma 76.42 17.03 98 14917 87517 64396200
Hallucination, auditory 75.97 17.03 48 14967 16891 64466826
Homicidal ideation 73.84 17.03 28 14987 3229 64480488
Pneumonia aspiration 71.05 17.03 78 14937 59193 64424524
Bruxism 70.93 17.03 28 14987 3596 64480121
Intentional overdose 69.79 17.03 95 14920 89849 64393868
Mania 67.71 17.03 44 14971 16242 64467475
Salivary hypersecretion 66.31 17.03 39 14976 12074 64471643
Arthralgia 65.44 17.03 12 15003 442248 64041469
Parkinsonism 65.13 17.03 41 14974 14332 64469385
Drug interaction 61.97 17.03 205 14810 361878 64121839
Dyskinesia 61.96 17.03 60 14955 39328 64444389
Pain 61.59 17.03 26 14989 553485 63930232
Completed suicide 59.72 17.03 149 14866 224265 64259452
Blood creatine phosphokinase increased 58.26 17.03 70 14945 58488 64425229
Dystonia 55.03 17.03 41 14974 18824 64464893
Tachycardia 52.70 17.03 111 14904 149468 64334249
Dyspnoea 52.67 17.03 54 14961 718620 63765097
Choreoathetosis 50.01 17.03 17 14998 1430 64482287
Pain in extremity 49.91 17.03 6 15009 303079 64180638
Poisoning deliberate 47.86 17.03 33 14982 13425 64470292
Delusion of grandeur 46.08 17.03 13 15002 587 64483130
Altered state of consciousness 45.61 17.03 50 14965 37852 64445865
Muscle rigidity 44.43 17.03 35 14980 17438 64466279
Trismus 44.26 17.03 22 14993 4879 64478838
Hyperkinesia 44.05 17.03 18 14997 2528 64481189
Delusion 41.38 17.03 34 14981 17980 64465737
Suicidal ideation 39.55 17.03 62 14953 66480 64417237
Affect lability 39.12 17.03 25 14990 8965 64474752
Delirium 39.10 17.03 63 14952 69131 64414586
Psychomotor retardation 37.52 17.03 20 14995 5123 64478594
Mutism 37.32 17.03 15 15000 2019 64481698
Depressed level of consciousness 36.62 17.03 67 14948 81369 64402348
Priapism 36.38 17.03 18 14997 3952 64479765
Torsade de pointes 36.22 17.03 31 14984 17332 64466385
Joint swelling 36.10 17.03 4 15011 215378 64268339
Mental disorder 35.55 17.03 37 14978 26408 64457309
Respiratory depression 35.53 17.03 35 14980 23408 64460309
Irritability 35.03 17.03 43 14972 36703 64447014
Mood altered 34.30 17.03 29 14986 15950 64467767
Schizophrenia 34.20 17.03 25 14990 11143 64472574
Coordination abnormal 33.86 17.03 28 14987 14936 64468781
Stereotypy 33.50 17.03 11 15004 831 64482886
Grandiosity 33.45 17.03 10 15005 555 64483162
Confusional state 32.09 17.03 133 14882 261011 64222706
Congenital cerebrovascular anomaly 31.34 17.03 5 15010 10 64483707
Abnormal behaviour 29.90 17.03 38 14977 33584 64450133
Seizure 29.80 17.03 96 14919 166796 64316921
Intentional product misuse 29.42 17.03 57 14958 72238 64411479
Floppy iris syndrome 28.89 17.03 8 15007 337 64483380
Crying 28.61 17.03 29 14986 20061 64463656
Speech disorder 28.59 17.03 45 14970 48396 64435321
Lactate pyruvate ratio increased 28.31 17.03 6 15009 79 64483638
Treatment noncompliance 27.92 17.03 42 14973 43440 64440277
Epileptic encephalopathy 27.53 17.03 8 15007 402 64483315
Encephalopathy 27.21 17.03 49 14966 58770 64424947
Blood folate decreased 27.21 17.03 10 15005 1057 64482660
Cardiac arrest 26.94 17.03 88 14927 153976 64329741
Myocarditis 26.86 17.03 26 14989 17017 64466700
Hepatocellular injury 26.67 17.03 42 14973 45193 64438524
Neutrophil count increased 26.52 17.03 31 14984 25143 64458574
Bradyphrenia 26.44 17.03 20 14995 9386 64474331
Peripheral swelling 26.30 17.03 8 15007 209145 64274572
Disorganised speech 26.29 17.03 11 15004 1639 64482078
Streptococcal infection 25.80 17.03 18 14997 7461 64476256
Hypersensitivity 25.65 17.03 7 15008 196445 64287272
Eosinophilic myocarditis 25.54 17.03 9 15006 843 64482874
Diarrhoea 25.44 17.03 85 14930 722619 63761098
Infusion related reaction 25.29 17.03 4 15011 164463 64319254
Drug-induced liver injury 25.05 17.03 42 14973 47601 64436116
Cardio-respiratory arrest 24.72 17.03 64 14951 98329 64385388
Hyperprolactinaemia 24.67 17.03 14 15001 4051 64479666
Pruritus 24.51 17.03 22 14993 312378 64171339
Miosis 24.30 17.03 22 14993 13244 64470473
Acanthosis nigricans 24.28 17.03 6 15009 161 64483556
Antipsychotic drug level increased 24.20 17.03 15 15000 5100 64478617
Anticholinergic syndrome 24.16 17.03 12 15003 2657 64481060
Long QT syndrome 24.13 17.03 15 15000 5124 64478593
Blood citric acid increased 24.10 17.03 5 15010 59 64483658
Myalgia 24.07 17.03 4 15011 158613 64325104
Drug intolerance 23.98 17.03 7 15008 187985 64295732
Spasmodic dysphonia 23.86 17.03 6 15009 173 64483544
Fatigue 23.74 17.03 92 14923 748638 63735079
Behaviour disorder 23.46 17.03 14 15001 4448 64479269
Myoclonus 23.30 17.03 29 14986 25089 64458628
Headache 23.23 17.03 56 14959 529411 63954306
Back pain 22.95 17.03 15 15000 250156 64233561
Abdominal discomfort 22.87 17.03 7 15008 182315 64301402
Swelling 22.29 17.03 5 15010 160213 64323504
Abortion 22.28 17.03 9 15006 1227 64482490
Restlessness 22.16 17.03 36 14979 39749 64443968
Dysarthria 21.96 17.03 45 14970 59361 64424356
Hallucinations, mixed 21.89 17.03 15 15000 6037 64477680
Parkinsonian gait 21.81 17.03 8 15007 841 64482876
Poisoning 21.49 17.03 26 14989 21853 64461864
Tremor 21.01 17.03 79 14936 148151 64335566
Akathisia 20.91 17.03 19 14996 11491 64472226
Affective disorder 20.76 17.03 15 15000 6565 64477152
Portal tract inflammation 20.53 17.03 5 15010 126 64483591
Drug screen false positive 20.44 17.03 8 15007 1004 64482713
Cerebral amyloid angiopathy 20.35 17.03 6 15009 317 64483400
Hepatic enzyme increased 20.34 17.03 3 15012 129940 64353777
Torticollis 20.33 17.03 10 15005 2167 64481550
Illusion 20.20 17.03 9 15006 1561 64482156
Schizoaffective disorder 20.11 17.03 9 15006 1578 64482139
Depressed mood 20.04 17.03 35 14980 40977 64442740
Drug resistance 19.87 17.03 32 14983 35070 64448647
Nausea 19.85 17.03 105 14910 785695 63698022
Rash 19.71 17.03 49 14966 458500 64025217
Echolalia 19.60 17.03 6 15009 361 64483356
Drug use disorder 19.56 17.03 14 15001 6040 64477677
Neuroblastoma 19.27 17.03 5 15010 164 64483553
Cough 18.53 17.03 26 14989 302122 64181595
Withdrawal syndrome 18.48 17.03 25 14990 23467 64460250
Mixed anxiety and depressive disorder 18.46 17.03 5 15010 194 64483523
Sleep disorder 18.37 17.03 42 14973 59667 64424050
Cogwheel rigidity 17.79 17.03 10 15005 2843 64480874
Sinus tachycardia 17.75 17.03 29 14986 32159 64451558
White blood cell count increased 17.68 17.03 44 14971 65970 64417747
Psychomotor skills impaired 17.49 17.03 11 15004 3834 64479883
Pneumoconiosis 17.37 17.03 5 15010 243 64483474
Hyperammonaemia 17.31 17.03 16 14999 9888 64473829
Neutropenia 17.28 17.03 105 14910 239519 64244198
Physical assault 17.17 17.03 8 15007 1538 64482179

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05AA01 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Phenothiazines with aliphatic side-chain
FDA CS M0016525 Phenothiazines
CHEBI has role CHEBI:37930 phenothiazine antipsychotic drugs
CHEBI has role CHEBI:48561 dopaminergic antagonists
CHEBI has role CHEBI:50919 antiemetico
CHEBI has role CHEBI:76779 post-proline endopeptidase inhibitors
CHEBI has role CHEBI:149553 anticoronaviral drug
MeSH PA D000932 Antiemetics
MeSH PA D014150 Antipsychotic Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D015259 Dopamine Agents
MeSH PA D018492 Dopamine Antagonists
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014149 Tranquilizing Agents
FDA EPC N0000175746 Phenothiazine

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Nausea and vomiting indication 16932000
Disruptive behavior disorder indication 54319003
Schizophrenia indication 58214004 DOID:5419
Psychotic disorder indication 69322001
Bipolar affective disorder, current episode manic indication 191618007
Acute intermittent porphyria indication 234422006 DOID:3890
Pre-Op Apprehension indication
Tetanus Adjunct Treatment indication
Intractable Hiccups indication
Alcoholism contraindication 7200002
Organophosphate poisoning contraindication 8260003
Weight gain finding contraindication 8943002
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Senile dementia contraindication 15662003
Chronic disease of respiratory system contraindication 17097001
Myocardial infarction contraindication 22298006 DOID:5844
Glaucoma contraindication 23986001 DOID:1686
Orthostatic hypotension contraindication 28651003
Torsades de pointes contraindication 31722008
Parkinsonism contraindication 32798002
Conduction disorder of the heart contraindication 44808001
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Extrapyramidal disease contraindication 76349003
Hyperglycemia contraindication 80394007 DOID:4195
Epilepsy contraindication 84757009 DOID:1826
Leukopenia contraindication 84828003 DOID:615
Stupor contraindication 89458003
Tardive dyskinesia contraindication 102449007
Prolonged QT interval contraindication 111975006
Acute disease of cardiovascular system contraindication 128487001
Angina pectoris contraindication 194828000
Disease of liver contraindication 235856003 DOID:409
Metabolic syndrome X contraindication 237602007 DOID:14221
Hyperprolactinemia contraindication 237662005 DOID:12700
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Anemia contraindication 271737000 DOID:2355
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Coma contraindication 371632003
At risk for aspiration contraindication 371736008
Visual impairment contraindication 397540003
Breastfeeding (mother) contraindication 413712001
Myocardial ischemia contraindication 414795007 DOID:3393
Obesity contraindication 414916001 DOID:9970
Congenital long QT syndrome contraindication 442917000
Carcinoma of female breast contraindication 447782002
Smokes tobacco daily contraindication 449868002




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.04 Basic
pKa2 2.21 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
100MG/ML CHLORPROMAZINE HYDROCHLORIDE GENUS A214542 June 2, 2021 RX CONCENTRATE ORAL Jan. 29, 2022 COMPETITIVE GENERIC THERAPY
30MG/ML CHLORPROMAZINE HYDROCHLORIDE GENUS A214542 June 2, 2021 RX CONCENTRATE ORAL Jan. 29, 2022 COMPETITIVE GENERIC THERAPY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
D(2) dopamine receptor GPCR ANTAGONIST Ki 8.15 WOMBAT-PK CHEMBL
Mu-type opioid receptor GPCR Ki 5.23 DRUG MATRIX
D(1A) dopamine receptor GPCR Ki 7.19 WOMBAT-PK
Alpha-2A adrenergic receptor GPCR Ki 6.20 WOMBAT-PK
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 6.72 DRUG MATRIX
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 5.83 WOMBAT-PK
Multidrug resistance protein 1 Transporter Ki 6.22 CHEMBL
Sodium-dependent serotonin transporter Transporter IC50 6.92 CHEMBL
Sodium-dependent noradrenaline transporter Transporter Ki 7.72 DRUG MATRIX
5-hydroxytryptamine receptor 1A GPCR Ki 6.17 CHEMBL
5-hydroxytryptamine receptor 2A GPCR ANTAGONIST Ki 8.10 WOMBAT-PK
5-hydroxytryptamine receptor 2B GPCR Ki 7.28 CHEMBL
5-hydroxytryptamine receptor 2C GPCR Ki 7.40 WOMBAT-PK
5-hydroxytryptamine receptor 6 GPCR Ki 7.44 WOMBAT-PK
5-hydroxytryptamine receptor 7 GPCR Ki 7.41 WOMBAT-PK
Alpha-1A adrenergic receptor GPCR Ki 9.55 PDSP
Alpha-2B adrenergic receptor GPCR Ki 7.60 WOMBAT-PK
D(3) dopamine receptor GPCR ANTAGONIST Ki 8.54 WOMBAT-PK
D(1B) dopamine receptor GPCR Ki 6.93 WOMBAT-PK
Histamine H1 receptor GPCR Ki 8.20 WOMBAT-PK
Histamine H2 receptor GPCR Ki 6.76 PDSP
Histamine H4 receptor GPCR Ki 6.87 WOMBAT-PK
Muscarinic acetylcholine receptor M1 GPCR Ki 7.60 PDSP
Muscarinic acetylcholine receptor M2 GPCR Ki 6.75 PDSP
Muscarinic acetylcholine receptor M3 GPCR Ki 7.25 PDSP
Muscarinic acetylcholine receptor M4 GPCR Ki 7.40 PDSP
Muscarinic acetylcholine receptor M5 GPCR Ki 7.38 PDSP
Aldehyde oxidase Enzyme IC50 6.24 WOMBAT-PK
5-hydroxytryptamine receptor 1B GPCR Ki 5.83 PDSP
5-hydroxytryptamine receptor 1D GPCR Ki 6.35 PDSP
Alpha-2C adrenergic receptor GPCR Ki 7.10 WOMBAT-PK
Sodium-dependent dopamine transporter Transporter Ki 5.68 DRUG MATRIX
Cytochrome P450 2D6 Enzyme Ki 5.16 WOMBAT-PK
D(4) dopamine receptor GPCR ANTAGONIST Ki 7.69 WOMBAT-PK
Alpha-1D adrenergic receptor GPCR Ki 8.71 DRUG MATRIX
5-hydroxytryptamine receptor 3A Ion channel Ki 6.01 PDSP
Alpha-1B adrenergic receptor GPCR Ki 9.09 PDSP
Kappa-type opioid receptor GPCR Ki 5.35 DRUG MATRIX
Calmodulin Cytosolic other Kd 5.91 CHEMBL
Delta-type opioid receptor GPCR Ki 5.13 DRUG MATRIX
5-hydroxytryptamine receptor 5A GPCR Ki 6.93 PDSP
5-hydroxytryptamine receptor 1E GPCR Ki 6.46 PDSP
Epidermal growth factor receptor Kinase IC50 4.54 DRUG MATRIX
Potassium channel subfamily K member 2 Ion channel IC50 5.57 CHEMBL
Tyrosine-protein kinase Fyn Kinase IC50 5.06 DRUG MATRIX
Receptor tyrosine-protein kinase erbB-2 Kinase IC50 4.71 DRUG MATRIX
Ryanodine receptor 1 Ion channel IC50 3.57 WOMBAT-PK
Major prion protein Surface antigen EC50 5.70 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 4.57 CHEMBL
Substance-K receptor GPCR Ki 5.04 DRUG MATRIX
Melanocortin receptor 4 GPCR Ki 4.84 DRUG MATRIX
Melanocortin receptor 5 GPCR Ki 5.15 DRUG MATRIX
Melanocortin receptor 3 GPCR Ki 4.67 DRUG MATRIX
Glutamate [NMDA] receptor Ion channel IC50 6.22 CHEMBL
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel IC50 5.37 CHEMBL
FAD-linked sulfhydryl oxidase ALR Enzyme AC50 5.99 CHEMBL
Sphingomyelin phosphodiesterase Enzyme IC50 4.96 CHEMBL
Solute carrier family 22 member 2 Transporter IC50 4.85 WOMBAT-PK
Trypanothione reductase Enzyme Ki 5.49 CHEMBL
Arachidonate 15-lipoxygenase Enzyme IC50 4.80 DRUG MATRIX
Alpha-1B adrenergic receptor GPCR Ki 8.31 DRUG MATRIX
5-hydroxytryptamine receptor 1B GPCR Ki 5.74 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 5.78 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR IC50 8.07 CHEMBL
Histamine H1 receptor GPCR Ki 7.30 CHEMBL
D(2) dopamine receptor GPCR Ki 8.92 CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 6.75 CHEMBL
5-hydroxytryptamine receptor 7 GPCR Ki 7.68 CHEMBL
5-hydroxytryptamine receptor 7 GPCR ANTAGONIST Ki 5.30 IUPHAR
D(1A) dopamine receptor GPCR Ki 7.46 CHEMBL
D(2) dopamine receptor GPCR IC50 7.10 CHEMBL
Transient receptor potential cation channel subfamily V member 1 Ion channel Ki 5.89 CHEMBL
5-hydroxytryptamine receptor 6 GPCR ANTAGONIST Ki 8.40 IUPHAR
Pleiotropic ABC efflux transporter of multiple drugs Transporter IC50 5.35 CHEMBL
Acetylcholine receptor subunit alpha Ion channel IC50 5.89 CHEMBL
Glutamate NMDA receptor Ion channel IC50 5.89 CHEMBL
Muscarinic acetylcholine receptor GPCR Ki 7.22 CHEMBL
Dopamine receptor GPCR IC50 7.60 CHEMBL
Dopamine receptor GPCR Ki 7.85 CHEMBL
Serotonin 2 (5-HT2) receptor GPCR Ki 9.15 CHEMBL
Adenylate cyclase Enzyme Ki 6.93 CHEMBL
Calmodulin Cytosolic other IC50 5.60 CHEMBL
Major prion protein Unclassified EC50 5.70 CHEMBL
Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 Enzyme IC50 4.64 CHEMBL

External reference:

IDSource
4017861 VUID
N0000146214 NUI
D00270 KEGG_DRUG
69-09-0 SECONDARY_CAS_RN
104728 RXNORM
4017860 VANDF
4017861 VANDF
C0008286 UMLSCUI
CHEBI:3647 CHEBI
CHEMBL71 ChEMBL_ID
CHEMBL1713 ChEMBL_ID
DB00477 DRUGBANK_ID
D002746 MESH_DESCRIPTOR_UI
2726 PUBCHEM_CID
83 IUPHAR_LIGAND_ID
183 INN_ID
U42B7VYA4P UNII
2140 MMSL
4264 MMSL
4428 MMSL
4429 MMSL
71853 MMSL
d00064 MMSL
001470 NDDF
004587 NDDF
387258005 SNOMEDCT_US
387479008 SNOMEDCT_US
47331002 SNOMEDCT_US
Z80 PDB_CHEM_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
CHLORPROMAZINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0404-9836 INJECTION 25 mg INTRAMUSCULAR ANDA 12 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-2961 TABLET, COATED 10 mg ORAL ANDA 14 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-2962 TABLET, COATED 25 mg ORAL ANDA 14 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-2963 TABLET, COATED 50 mg ORAL ANDA 14 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-2964 TABLET, COATED 100 mg ORAL ANDA 14 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-2965 TABLET, COATED 200 mg ORAL ANDA 14 sections
Chlorpromazine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0641-1397 INJECTION 25 mg INTRAMUSCULAR ANDA 17 sections
Chlorpromazine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0641-1398 INJECTION 25 mg INTRAMUSCULAR ANDA 17 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-5913 TABLET, SUGAR COATED 10 mg ORAL ANDA 17 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-5914 TABLET, SUGAR COATED 25 mg ORAL ANDA 17 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-5915 TABLET, SUGAR COATED 50 mg ORAL ANDA 17 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-5916 TABLET, SUGAR COATED 100 mg ORAL ANDA 17 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-5917 TABLET, SUGAR COATED 200 mg ORAL ANDA 17 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0300 TABLET, SUGAR COATED 10 mg ORAL ANDA 14 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0301 TABLET, SUGAR COATED 25 mg ORAL ANDA 14 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0302 TABLET, SUGAR COATED 50 mg ORAL ANDA 14 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0303 TABLET, SUGAR COATED 100 mg ORAL ANDA 14 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0304 TABLET, SUGAR COATED 200 mg ORAL ANDA 14 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-6017 TABLET, FILM COATED 10 mg ORAL ANDA 17 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-6018 TABLET, FILM COATED 25 mg ORAL ANDA 17 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-6019 TABLET, FILM COATED 50 mg ORAL ANDA 17 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-6020 TABLET, FILM COATED 100 mg ORAL ANDA 17 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-6021 TABLET, FILM COATED 200 mg ORAL ANDA 17 sections
CHLORPROMAZINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0904-6892 TABLET, FILM COATED 10 mg ORAL ANDA 13 sections
CHLORPROMAZINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0904-6893 TABLET, FILM COATED 25 mg ORAL ANDA 13 sections
CHLORPROMAZINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0904-6894 TABLET, FILM COATED 50 mg ORAL ANDA 13 sections
CHLORPROMAZINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0904-6895 TABLET, FILM COATED 100 mg ORAL ANDA 13 sections
CHLORPROMAZINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0904-6896 TABLET, FILM COATED 200 mg ORAL ANDA 13 sections
Chlorpromazine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-7129 TABLET, FILM COATED 10 mg ORAL ANDA 13 sections
Chlorpromazine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-7130 TABLET, FILM COATED 25 mg ORAL ANDA 13 sections